Rita Chiari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6056108/publications.pdf

Version: 2024-02-01

126	7,285	94433 37	71685 76
papers	citations	h-index	g-index

129	129	129	8542
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, The, 2017, 389, 917-929.	13.7	919
2	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncology, The, 2018, 19, 1654-1667.	10.7	587
3	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2021, 39, 723-733.	1.6	329
4	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 1370-1379.	1.6	282
5	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
6	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 479-485.	2.5	253
7	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 1691-1701.	10.7	233
8	Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 2195-2202.	7.0	208
9	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. Journal of Thoracic Oncology, 2015, 10, 1437-1443.	1.1	163
10	Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 707-715.	1.1	160
11	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€“Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	7.0	139
12	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745.	1.6	138
13	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	3.7	131
14	Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical Oncology, 2016, 33, 18.	2.5	129
15	Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology, 2017, 35, 1281-1287.	1.6	126
16	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
17	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
18	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. , 2019, 7, 316.		102

#	Article	IF	Citations
19	CSF Concentration of Crizotinib in Two ALK-Positive Nonâ€“Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. Journal of Thoracic Oncology, 2015, 10, e26-e27.	1.1	93
20	A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics. Journal of Thoracic Oncology, 2019, 14, 130-134.	1.1	92
21	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116.		88
22	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
23	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81
24	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
25	Italian Nivolumab Expanded Access Program inÂNonsquamous Nonâ€“Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155.	1.1	77
26	Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer, 2012, 78, 81-86.	2.0	68
27	Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. British Journal of Cancer, 2019, 120, 57-62.	6.4	68
28	c-Met targeting in advanced gastric cancer: An open challenge. Cancer Letters, 2015, 365, 30-36.	7.2	67
29	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunology, Immunotherapy, 2020, 69, 1177-1187.	4.2	66
30	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥â€‰50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	4.2	60
31	ROS1-rearranged Nonâ€“small-cell Lung Cancer isÂAssociated With a High Rate of VenousÂThromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms TrialÂ(METROS). Clinical Lung Cancer, 2020, 21, 15-20.	2.6	58
32	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression â‰¥ 50%: a multicenter study with external validation. , 2020, 8, e001403.		57
33	Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types. Molecular Imaging and Biology, 2019, 21, 1200-1209.	2.6	53
34	Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2011, 6, 2018-2026.	1.1	50
35	Future options for ALK-positive non-small cell lung cancer. Lung Cancer, 2015, 87, 211-219.	2.0	50
36	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 ExpressionÂâ‰¥ 50% and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	2.6	50

#	Article	IF	Citations
37	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Medical Oncology, 2017, 34, 105.	2.5	47
38	Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. Journal of Clinical Medicine, 2020, 9, 1047.	2.4	47
39	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
40	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. Lung Cancer, 2015, 90, 255-260.	2.0	43
41	Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2019, 8, 131.	2.4	42
42	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Nonâ€“Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. Clinical Lung Cancer, 2014, 15, 86-92.	2.6	40
43	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. Clinical Lung Cancer, 2019, 20, e186-e194.	2.6	40
44	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2021, 165, 103436.	4.4	40
45	Antitumor Immunity at Work in a Melanoma Patient. Advances in Cancer Research, 1999, 76, 213-242.	5.0	39
46	Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thrombosis Research, 2015, 136, 924-927.	1.7	39
47	Long-Term Response to Gefitinib and Crizotinib in Lung Adenocarcinoma Harboring Both Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion Gene. Journal of Clinical Oncology, 2014, 32, e30-e32.	1.6	38
48	Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis. Oncotarget, 2016, 7, 30561-30574.	1.8	37
49	Safety and Efficacy of Nivolumab in Patients With Advanced Nonâ€“small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer, 2019, 20, 178-185.e2.	2.6	35
50	Optimal management of ALK -positive NSCLC progressing on crizotinib. Lung Cancer, 2017, 106, 58-66.	2.0	33
51	Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases. Anticancer Research, 2019, 39, 4265-4271.	1.1	33
52	Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2014, 15, 411-417.e4.	2.6	32
53	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer, 2016, 99, 31-37.	2.0	31
54	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	3.2	30

#	Article	IF	Citations
55	Smoking status during firstâ€line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A caseâ€“control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	1.9	30
56	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Medical Oncology, 2018, 35, 72.	2.5	29
57	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer, 2019, 138, 79-87.	2.0	29
58	Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. Frontiers in Immunology, 2020, 11, 839.	4.8	28
59	Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-NaÃ¯ve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clinical Drug Investigation, 2016, 36, 683-686.	2.2	27
60	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 159-168.	2.8	27
61	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2022, 169, 103567.	4.4	26
62	Alectinibâ€™s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361.	2.9	25
63	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	3.7	25
64	Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clinic Proceedings, 2017, 92, 1304-1311.	3.0	24
65	Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276.	1.8	24
66	Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 4403.	4.1	24
67	Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	2.8	24
68	The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. Journal of Clinical Medicine, 2021, 10, 1005.	2.4	23
69	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 2601-2613.	1.8	22
70	Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880865.	2.6	22
71	Selumetinib: a promising pharmacologic approach forKRAS-mutant advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 167-177.	2.4	19
72	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87.	2.0	19

#	Article	IF	Citations
73	Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19
74	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Nonâ€“Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clinical Cancer Research, 2022, 28, 2506-2516.	7.0	19
75	Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 140, 140-146.	2.8	18
76	Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Radiologia Medica, 2021, 126, 1117-1128.	7.7	18
77	Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol: TableÂ1. BMJ Open, 2016, 6, e010547.	1.9	17
78	Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Medical Oncology, 2018, 35, 4.	2.5	17
79	Antibodyâ€“drug conjugates for lung cancer in the era of personalized oncology. Seminars in Cancer Biology, 2021, 69, 268-278.	9.6	17
80	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987772.	3.2	16
81	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. Oncologist, 2021, 26, e1854-e1861.	3.7	16
82	Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. Journal of Thoracic Oncology, 2018, 13, e145-e147.	1.1	15
83	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study. European Journal of Cancer, 2021, 147, 120-127.	2.8	15
84	Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. Journal of Breast Cancer, 2016, 19, 324.	1.9	14
85	Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clinical Drug Investigation, 2018, 38, 983-987.	2.2	14
86	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Genes, 2021, 12, 273.	2.4	14
87	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	4.4	14
88	Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. Clinical Lung Cancer, 2014, 15, 470-474.	2.6	13
89	miRNAs and resistance to EGFRâ€”TKIs in EGFR-mutant non-small cell lung cancer: beyond â€˜traditional mechanismsâ€™ of resistance. Ecancermedicalscience, 2015, 9, 569.	1.1	12
90	Fatal acute disseminated intravascular coagulation as presentation of advanced ALK -positive non-small cell lung cancer: Does oncogene addiction matter?. Thrombosis Research, 2018, 163, 51-53.	1.7	12

#	Article	IF	Citations
91	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 2019, 134, 210-217.	2.0	12
92	Sensitivity and specificity of breast cancer ICD-9-CM codes in three Italian administrative healthcare databases: a diagnostic accuracy study. BMJ Open, 2018, 8, e020627.	1.9	11
93	Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. JTO Clinical and Research Reports, 2021, 2, 100114.	1.1	11
94	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	4.2	11
95	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiologia Medica, 2020, 125, 214-219.	7.7	10
96	Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?. Journal of Thoracic Disease, 2018, 10, S3890-S3894.	1.4	9
97	Accuracy of lung cancer ICD-9-CM codes in Umbria, Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study. BMJ Open, 2018, 8, e020628.	1.9	9
98	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. Tumori, 2022, 108, 250-257.	1.1	9
99	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 101-109.	2.4	8
100	Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. Journal of Thoracic Oncology, 2018, 13, e9-e12.	1.1	8
101	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer, 2020, 140, 71-79.	2.0	8
102	KRAS mutation and DNA repair and synthesis genes in nonâ€'smallâ€'cell lung cancer. Molecular and Clinical Oncology, 2018, 9, 689-696.	1.0	7
103	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge With Gefitinib. Cancers, 2019, 11, 1431.	3.7	7
104	Exploring metastatic breast cancer treatment changes during COVID-19 pandemic. Journal of Chemotherapy, 2021, 33, 263-268.	1.5	7
105	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <scp>PDâ€L1</scp> â‰¥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	1.9	7
106	Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 663-671.	2.8	6
107	Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland. Tumori, 2016, 102, S16-S21.	1.1	6
108	Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study. Oncotarget, 2017, 8, 83343-83353.	1.8	6

#	Article	IF	Citations
109	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer, 2018, 120, 70-74.	2.0	5
110	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: AÂModel From Lung Cancer. Clinical Lung Cancer, 2018, 19, 191-198.	2.6	5
111	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e220-e222.	1.1	5
112	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes, 2021, 12, 992.	2.4	5
113	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	17.0	5
114	Bronchiolitis Obliterans Organizing Pneumonia after Radiation Therapy for Lung Cancer: A Case Report. Tumori, 2015, 101, e88-e91.	1.1	4
115	Long-Lasting Response toÂNivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Nonâ€“Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55.	1.1	3
116	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 353-361.	2.4	3
117	Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. In Vivo, 2019, 33, 2021-2026.	1.3	3
118	Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020â€“Sep 2020; Sep 2020â€“May 2021) in the Veneto Oncology Network: The ROVID study. European Journal of Cancer, 2022, 167, 81-91.	2.8	3
119	How might treatment of ALK-positive non-small cell lung cancer change in the near future?. Expert Review of Anticancer Therapy, 2016, 16, 997-999.	2.4	2
120	First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. Translational Lung Cancer Research, 2018, 7, S127-S130.	2.8	2
121	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Nonâ€“small-cell Lung Cancer Progressing on Crizotinib. Clinical Lung Cancer, 2020, 21, e478-e487.	2.6	2
122	Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. Journal of Radiation Oncology, 2017, 6, 11-19.	0.7	1
123	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
124	Preface on â€œEmerging treatment options for brain metastases from non-small cell lung cancerâ€• Translational Lung Cancer Research, 2016, 5, 561-562.	2.8	1
125	Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. International Journal of Biological Markers, 2018, 33, 549-550.	1.8	0
126	Colonic metastases from non-small cell lung cancer. Revista Espanola De Enfermedades Digestivas, 2012, 104, 447-448.	0.3	0